Yescarta
Gilead’s $3B Oncology Milestone: Trodelvy, Tecartus and Yescarta Lead the Way in 2023
SG Tylor
Gilead Sciences has been making significant strides in the oncology space, fueled by the success of its rising star drug, ...
Kite Successfully Transfers Marketing Authorization for Yescarta CAR T-cell Therapy in Japan
SG Tylor
Source – Gilead Sciences According to Kite Pharma on June 22, 2023, the marketing authorization for Yescarta, a chimeric antigen ...
